Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Has Consensus Target Price of $30.25

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been given an average recommendation of “Hold” by the eleven research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $30.25.

Several equities analysts have issued reports on CAPR shares. Alliance Global Partners lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target on the stock. in a report on Tuesday, July 28th. Piper Sandler upgraded Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Tuesday, September 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Friday, September 11th. Oppenheimer reiterated an “outperform” rating on shares of Capricor Therapeutics in a research note on Thursday, October 8th. Finally, B. Riley Financial raised Capricor Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $5.00 to $21.00 in a report on Monday, September 14th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. KBC Group NV purchased a new position in Capricor Therapeutics during the first quarter valued at approximately $44,000. Activest Wealth Management lifted its holdings in Capricor Therapeutics by 100.0% in the third quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 2,000 shares during the period. SG Americas Securities LLC acquired a new position in Capricor Therapeutics in the first quarter valued at approximately $193,000. Pictet Asset Management Holding SA purchased a new stake in Capricor Therapeutics in the 1st quarter worth approximately $250,000. Finally, Quantinno Capital Management LP boosted its position in Capricor Therapeutics by 16.8% in the 1st quarter. Quantinno Capital Management LP now owns 14,472 shares of the biotechnology company’s stock worth $440,000 after purchasing an additional 2,083 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Down 3.6%

Shares of CAPR stock opened at $8.60 on Friday. The firm has a market cap of $500.00 million, a price-to-earnings ratio of -3.51 and a beta of 0.80. Capricor Therapeutics has a 52-week low of $2.96 and a 52-week high of $40.37. The company’s 50 day moving average is $8.10 and its 200 day moving average is $20.28.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Analysts anticipate that Capricor Therapeutics will post -1.71 EPS for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.